Slides
Page 1
Private and Confidential Sahajanand Medical Technologies Limited Investor Presentation Q2 FY2026-27
Page 2
Safe Harbor Statement 2 This presentation is not an offer, invitation, solicitation or recommendation to buy, sell or subscribe for any securities ofthe Company. It should not be the basis for any contract, commitment or investment decision. Any offering of securities will be made only through a formal offering document. Forward-looking statements This presentation contains statements about the Company’s future plans, strategy, expected performance, market opportunity, new products, regulatory approvals, capacity, costs, margins and industry outlook. These are "forward-looking statements". They are often, but not always, identified by words such as "expect", "anticipate", "believe", "intend", "plan", "estimate", "project", "may", "will", "should" and "target". Forward-looking statements are based onmanagement’s current views and assumptions. They are not guarantees of future performance. They involve known and unknown risks and uncertainties, many outside the Company’s control, so actual results may differ materially from what is stated or implied. Please do not place undue reliance on them. Factors that could cause results to differ These include, but are not limited to: economic, political and market conditions in India and in the countries where we operate, including inflation, interest rates, currency movements and geopolitical events; competition, pricing pressure and changes in customer demand; our ability to deliver on our strategy, growth and expansion plans, including acquisitions and their integration; regulatory approvals, inspections and compliance, and changes in laws; product development, clinical or technical outcomes and launch timelines; supply chain, input cost, manufacturing capacity and quality risks; intellectual property and litigation matters; quarter-to-quarter variations in revenue caused by order timing, deferrals or the nature of our business; technology, cybersecurity and operational disruptions; and other risks described in our regulatory filings. Accuracy of information We believe the information in this presentation is reliable, but we make no representation or warranty, express or implied, that it is accurate, complete or fair. It may not include everything you consider important. To the fullest extent permitted by law, the Company, its directors, officers and employees accept no liability for any loss arising from use of, or reliance on, this presentation. Financial information Figures are drawn from the Company’s financial results. Please read this presentation together with the full results and disclosures on the Company’s website (https://smtpl.com/) and on the websites of the BSE and NSE, the filed financial results prevail. Some measures used here, such as EBITDA, margins, return ratios are not defined under Ind AS, and may be calculated differently by other companies. Comparisons with earlier periods may be affected by acquisitions, one-off items or reclassification. Past performance is not a guide to future results. Third-party and industry data Market, industry and competitor data comes from sources we consider reliable. We have not independently verified it and do not guarantee it. Views or projections from third parties are not adopted by the Company, which is not responsible for them. Products and medical information Products or brands mentioned are for illustration only and are not an endorsement, advertisement or recommendation. Product information is general, may vary by country, and is not complete medical information or a substitute for advice from a qualified healthcare professional. Availability depends on local approvals and patents. No obligation to update This presentation speaks only as of its date. Except as required by law or by stock exchange regulations, the Company is not obliged to update or revise any information or forward-looking statement, whether because of new information, future events or otherwise. Distribution This presentation is not intended for distribution in any jurisdiction where doing so would be unlawful. Anyone receiving it should inform themselves of, and follow, any such restrictions.
Page 3
Contents Q2 and H1 FY27 investor presentation 1 Management commentary Message from the Managing Director and CEO 4 2 Q2 and H1 FY27 financial performance Results snapshot, product and regional mix, and financial KPIs: P&L, balance sheet and returns, cash conversion and cash flow 5 – 12 3 Operating KPIs and asset efficiency Global presence, capacity utilisation and fixed asset turnover 13 – 15 4 Product pipeline and regulatory progress Hydra TAVI, Hydra Elevate, AVDC 1.5, Sironity DCB and EU MDR status 16 – 21 5 Company overview Business model, products, R&D, manufacturing, leadership and board 22 – 30 Slides 3
Page 4
Management Commentary Q2 and H1 FY27: our first results as a listed company “ ” Q2 FY27 marks our first results as a listed company. I would like to thank our shareholders, physicians, partners and employees for the trust they placed in SMT through our listing on 23rd October 2026, and we remain committed to earning that trust through consistent execution. We delivered a strong first half. H1 FY27 revenue grew 25% to₹7,251 mn and EBITDA grew 43% to ₹1,141 mn, with the EBITDA margin expanding by about 200 basis points to 15.7%. Q2 FY27 was our best quarter yet, with the highest-ever quarterly revenue, EBITDA and PAT. We also strengthened our portfolio. Sironity, our sirolimus drug-coated balloon, is commercialized in India, and our TAVI platform has moved forward with Hydra Elevate and the redesigned AVDC 1.5 delivery system. Operational efficiency remains a key priority. We are focused on improving margins through a richer product mix, vertical integration of critical components, better utilisation of our plants and tighter control of overheads, to deliver profitable, sustainable growth. Our priorities are unchanged: disciplined execution, sustained investment in R&D and clinical evidence, and better quality of cash flows. Bhargav Dhirajlal Kotadia Managing Director and Chief Executive Officer 4
Page 5
Q2 and H1 FY27 Financial Performance
Page 6
Record Quarter: Highest-Ever Revenue, EBITDA and PAT in Q2 FY27 Revenue +25%, EBITDA +37% and PAT +27% year on year in Q2 FY27 Revenue EBITDA PAT Q2 FY27 ₹3,734 mn +24.7% YoY ₹656 mn +36.6% YoY 17.6% margin (Q2 FY26: 16.0%) ₹265 mn +26.6% YoY 7.1% margin (Q2 FY26: 7.0%) H1 FY27 ₹7,251 mn +24.9% YoY ₹1,141 mn +43.4% YoY 15.7% margin (H1 FY26: 13.7%) ₹416 mn +7.5% YoY 5.7% margin (H1 FY26: 6.7%) 6 ★ Record quarter +38.8% excl. one-off tax credit in H1 FY26
Page 7
Revenue mix and year-on-year growth by product category, Q1, Q2 and H1 FY27 H1 FY27 Revenue Up 25%, With Growth Across All Three Categories Q1 FY27 ₹3,517 mn +25.2% YoY 60.4%16.0% 23.6% YoY growth +24.0% +10.3% +41.7% Q2 FY27 ₹3,734 mn +24.7% YoY 55.7% 18.3% 26.1% YoY growth +9.1% +39.7% +62.1% H1 FY27 (Q1 + Q2) ₹7,251 mn +24.9% YoY 57.9% 17.2% 24.9% YoY growth +16.1% +24.7% +52.0% K E Y T A K E A W A Y S Other grew fastest: +42% in Q1 and +62% in Q2, led by IVUS SH accelerated: +40% in Q2 after +10% in Q1 VI remains the core: 58% of H1 revenue, up 16% year on year. VI Stents & balloons SH TAVI & occluders Other Trading products Growth % vs the same period of FY26. 7
Page 8
Revenue share and year-on-year growth by region, H1 FY27 H1 FY27 Revenue Up 25%, Led by RoW (+37%) and Europe (+23%) India 23.7% Share of H1 +10.4% H1 YoY growth ₹1,720 mn Q1 ₹838 mn +6.2% Q2 ₹882 mn +14.8% Europe 36.2% Share of H1 +23.4% H1 YoY growth ₹2,627 mn Q1 ₹1,320 mn +23.5% Q2 ₹1,307 mn +23.4% RoW (APAC, RCIS, LATAM, MEA) 40.0% Share of H1 +37.1% H1 YoY growth ₹2,904 mn Q1 ₹1,359 mn +42.8% Q2 ₹1,545 mn +32.4% K E Y T A K E A W A Y S India picked up: +15% in Q2 after +6% in Q1; share down to 24% as other regions grew faster. Europe steady: +23% in both quarters, holding about 36% of revenue. RoW grew fastest: +43% in Q1 and +32% in Q2; now 40% of H1 revenue, the largest region. 8
Page 9
Record Q2: EBITDA Up 37% and PAT Up 27% on 25% Revenue Growth Consolidated profit and loss summary, Q2 and H1 FY27 (₹ mn) 9 ₹ mn Q2 FY27 Q2 FY26 YoY H1 FY27 H1 FY26 YoY Revenue from operations 3,734 2,995 +24.7% 7,251 5,804 +24.9% Cost of goods sold (956) (708) (1,867) (1,396) Gross profit 2,778 2,287 +21.5% 5,384 4,408 +22.1% Gross margin 74.4% 76.4% -197 bps 74.3% 76.0% -170 bps Employee benefits expense (1,013) (863) (1,987) (1,721) % of revenue 27.1% 28.8% -169 bps 27.4% 29.7% -226 bps Other expenses (1,110) (945) (2,256) (1,891) % of revenue 29.7% 31.5% -182 bps 31.1% 32.6% -146 bps EBITDA 656 480 +36.6% 1,141 796 +43.4% EBITDA margin 17.6% 16.0% +154 bps 15.7% 13.7% +202 bps Other income 22 23 49 55 Depreciation (PPE and right-of-use assets) (165) (129) (321) (249) Amortisation of intangible assets¹ (44) (43) (92) (85) Finance costs (68) (60) (134) (118) Profit before tax 401 271 +47.9% 644 399 +61.2% Tax (current and deferred) (136) (62) (228) (100) Tax credit relating to earlier periods – – – 87 Profit after tax 265 209 +26.6% 416 386 +7.5% PAT margin 7.1% 7.0% +11 bps 5.7% 6.7% -93 bps PAT excluding earlier-period tax credit 265 209 +26.6% 416 299 +38.8% ¹ Mainly brand & technology and customer relationships recognized on past acquisitions. These intangibles will be fully amortized by Mar 2027, after which this charge will largely cease. Revenue growth in constant currency Q2 FY27 ~16% reported 24.7% H1 FY27 ~15% reported 24.9%
Page 10
Balance sheet in sources and application of funds format (₹ mn) Returns Improving: ROCE at 16.7% and ROE at 11.2% ₹ mn 30-Sep-26 31-Mar-26 Total Equity 7,453 7,023 Borrowings 3,017 2,695 Sources of Funds 10,470 9,718 Fixed Assets 3,537 3,524 Net Non-current Assets / (Liabilities) 787 794 Inventory (At Cost) 3,303 3,091 Trade Receivables 3,181 2,863 Trade Payables & Other current Liabilities (net of assets) (1,481) (1,669) Net Working Capital 5,003 4,285 Capital Employed 9,327 8,602 Cash & Cash Equivalents 1,143 1,116 Application of Funds 10,470 9,718 ROCE (EBIT / capital employed) 16.7%* 12.2% ROE (PAT / total equity) 11.2%* 9.8% 10 * Annualised: Sep-26 ROCE and ROE use H1 FY27 EBIT × 2 and PAT × 2 respectively.
Page 11
Receivable, inventory and payable days, FY25 to H1 FY27 Sharper Focus on Cash Conversion: Cycle Down 16 Days to 128 144 138 128 85 83 75 92 87 79 (33) (32) (26) FY25 FY26 H1 FY27 Receivable days Inventory days Payable days CCC days D A Y S Days FY25 FY26 H1 FY27 Receivable days 85 83 75 Inventory days 92 87 79 Payable days 33 32 26 Cash conversion cycle 144 138 128 W H A T M O V E D , F Y 2 6 T O H 1 F Y 2 7 −8 days Receivables faster collections −8 days Inventory leaner stock +6 days Payables 11
Page 12
Cash conversion, free cash flow and leverage, FY24 to H1 FY27 (₹ mn) Cash From Operations Up 2.6x Since FY24, Converting 62% of EBITDA EBITDA Cash from operations CFO / EBITDA 37% 57% 62% 1,100 1,280 1,707 1,141 411 735 1,052 473 FY24 FY25 FY26 H1 FY27 C A S H F L O W ₹ mn FY24 FY25 FY26 H1 FY27 Cash from operations 411 735 1,052 473 Net capex (393) (477) (884) (415) Lease payments (116) (94) (152) (76) Free cash flow after leases (before interest on borrowings) (98) 164 16 (18) L E V E R A G E Net debt (period end) 951 1,159 1,911 2,235 Net debt / EBITDA 0.86x 0.91x 1.12x 0.98x* 12 41% * Annualised: net debt / EBITDA for H1 FY27 uses H1 EBITDA × 2. H1 FY27 cash flows are for six months.
Page 13
Operating KPIs and Asset Efficiency
Page 14
Broad Global Reach, With Ample Manufacturing Headroom Countries with commercial presence, installed capacity and capacity utilisation by product and plant 14 Countries with commercial presence 75 75 77 70 FY24 FY25 FY26 H1 FY27 Installed capacity and utilisation Capacity (units p.a.) Capacity utilisation Product Plant / line FY26 H1 FY27 FY26 H1 FY27 Surat 780,000 780,000 80% 79% Telangana 120,000 180,000 64% 20% DES PTCA · Surat 660,000 660,000 97% 72% PTCA · Telangana 480,000 600,000 85% 57% DCB · Surat New – 56,000 – 40% Balloon Thailand 3,000 3,600 60% 53%TAVI Thailand 30,000 30,000 48% 46%Occluder 85%+ 65–85% 40–65% <40% Orange: capacity added or new line in H1 FY27 Countries: commercial presence with at least one product in the period; the H1 FY27 count is not directly comparable with full-year counts. Capacity utilisation = production ÷ installed capacity for the period; H1 FY27 uses half of annual capacity.
Page 15
Asset-Light Model, With Telangana Capacity in Place for Growth Gross tangible fixed asset turnover ratio (GTFAT), before and after the Telangana Plant came on stream 15 GTFAT, FY20–H1 FY27 7.8x 7.4x 6.5x 4.4x 3.4x 3.5x 3.4x 3.4x FY20 FY21 FY22 FY23 FY24 FY25 FY26 H1 FY27* Pre-Telangana Plant Post-Telangana Plant Average GTFAT 7.2x Average GTFAT, FY23–FY26 3.7x Telangana Plant (FY26) Plant area in use 33% DES capacity utilised 64% Catheter capacity utilised 85% 56% of gross block sits at the Telangana Plant * Annualised: H1 FY27 revenue × 2.
Page 16
Product Pipeline and Regulatory Progress
Page 17
Hydra TAVI Built Through Continuous Clinical Iteration Valve and delivery system refined generation by generation, each step backed by clinical data 17 Clinical and regulatory milestones 2017 First-in-man 15 patients 2020 Acquired with Vascular Concepts / Innovations 2021 Genesis study 40 patients 2022 Hydra CE study 157 patients 2024 Genesis-II PPI 7.5% at 30 days FY26 AVDC 1.5 CE approval Valve Hydra Nitinol frame, bovine leaflets, internal skirt · CE mark | CDSCO Hydra Elevate + polymeric external skirt to seal the annulus · CDSCO (Jan 2026) Delivery system AVDC 1.0 Patented system, developed after the acquisition · CE mark | CDSCO AVDC 1.5 Braided capsule, zero-lag release, fewer rotations · CE approval FY26 PPI: permanent pacemaker implantation. Jan 2026 Hydra 2.0 CDSCO approval
Page 18
Hydra Elevate: The Proven Hydra Valve, Plus an External Skirt Same platform carried forward; a polymeric external skirt added to seal the annulus 18 Existing: Hydra • Nitinol self-expanding frame • Bovine leaflets, internal skirt • Supra-annular leaflet position • Re-sheathable and repositionable Approvals: CE mark | CDSCO New: Hydra Elevate (TAVI 2.0) • Polymeric external skirt that seals the annulus • Designed to reduce paravalvular leak • Same frame, leaflets and internal skirt as Hydra Approvals: CDSCO + Polymeric external skirt Seals the annulus to reduce paravalvular leak
Page 19
AVDC 1.5: Redesigned for Stable, Predictable Deployment Refined from AVDC 1.0 with a braided capsule, longer in-line sheath and stronger shaft 19 Existing: AVDC 1.0 Patented delivery system developed after the Vascular Innovations acquisition CE mark | CDSCO New: AVDC 1.5 Next-generation delivery system; CE approval received in FY26 CE mark | CDSCO What's new in AVDC 1.5 Lag reduced to zero Direct 1:1 response between knob and capsule Fewer rotations to deploy Simpler, faster deployment Longer in-line sheath Better coaxial tracking and stability More robust shaft Greater pushability through the delivery path Ergonomic design Improves the user experience for the implanting physician
Page 20
Sironity: SMT’s Sirolimus Drug-Coated Balloon Brings together SMT’s drug-formulation and balloon platforms 20 Three design levers 1 Duo nano core formulation 2 Proven non-compliant balloon platform 3 Higher dose, full-circumference coating 84 sizes: 1.50–5.00 mm, 10–40 mm long Rapid exchange, 6F guide compatible 30–60 second inflation DCB: drug-coated balloon. ★ Commercialised in India
Page 21
Progress of each product through the EU MDR certification stages Supraflex Cruz Certified; Four More on Track Ahead of MDR Deadline Product Notified body Submitted Stage I audit Stage II audit Certified Supraflex Cruz EU MDR certification received. TUV SUD ● ● ● ✓ Pipit NC Stage I and II audits completed; technical documentation review underway. Szutest ● ● ● ○ Pipit SC Stage I and II audits completed; technical documentation review underway. Szutest ● ● ● ○ Hydra Technical file submitted; first reviewer questions answered. PCBC ● ○ ○ ○ Cocoon Technical file submitted; first reviewer questions answered. PCBC ● ○ ○ ○ ● Completed ○ Pending EU MDR transition period ends 31-Dec-2027. 21
Page 22
Company Overview
Page 23
Indian classification Class D Class C Class B Class A Coronary stents, Cardiac catherisation kits, Occlusion catheters etc.. Bone cement, Bifurcation stents and catheters, Anesthesia conduction filter, Introducer sheath, Microcatheter etc. Infusion bags, Endoscopic forceps, Vial adapters, Suction cups, Catheters, Needle kits, Cervical drains etc. Surgical dressings, Umbilical occlusion devices, Bolster sutures, Alcohol swabs, Nasopharyngeal catheters etc. Focused on Class III Medical Devices With High Entry Barriers Technical complexity, stringent scrutiny, large clinical data and KOL engagement requirements European classification Class III Class IIb Class IIa Class I Risk Classification Barriers to entry in Class III medical devices ✓ High-risk devices need substantial R&D investments and have long gestation periods ✓ Significant investments are required for clinical trials and building brand reputation ✓ Stringent regulations for approvals and extensive clinical data requirements ✓ Requirement of significant scientific selling and KOL engagements to drive adoption ✓ Prolonged approval timelines for high risk devices Segment with high entry barriers and sustainable technical moat Risk Classification 23
Page 24
Most deliverable and world’s 1st CE certified biodegradable polymer stent Comprehensive clinical coverage Indications CY 2019 > CY 2025 > De Novo Stenotic lesion ✓ ✓ Bifurcation Lesions ✓ Diabetic Patients ✓ DAPT / HBR ✓ Elderly Patients ✓ In-stent Restenosis (ISR) ✓ ✓ Multi Vessel PCI ✓ Small Vessel ✓ STEMI ✓ Left main (LM) disease ✓ SMT Numerically superior against leading brands 28,383 patients incl. high risk and geriatric patients World’s 1st CE approved biodegradable polymer coated DES Most Deliverable DES in its class, preferred in complex PCI Published in Impact factor 109.0 Impact factor 84.5 Technologically Advanced and “Most Deliverable” Stent in its Class… LANCET NEJM NEJM: New England Journal of Medicine Impact factor represents the average number of times articles published in a journal were cited in a given year TALENT all-comers trial: Supraflex was compared with Xience in a population open to almost any patient with the condition studied. At 12 months, Supraflex was non-inferior to Xience on device-oriented endpoints, with a lower rate of clinically indicated target lesion revascularisation in the per-protocol analysis. Source: TALENT clinical trial, 12-month results (Chairman: Dr Patrick W. Serruys) Commercialized in 71 markets b/w FY24-Jun’26 24
Page 25
…Along with Advanced Structural Heart Products (TAVI and Occluders) TAVI: Low permanent pacemaker implantation rate (PPI) Occluder: Platinum coated to minimize Nickel leaching 8% 7% 8% 11% 12% 14% 15% PPI after 30 days of implant (lower is better) Peer 1 Peer 2 Peer 3 Peer 4 Peer 5 Peer 6 Self expandable Nitinol stent frame TAVI ‘Hydra’ Commercialized in 36 markets b/w FY24-Jun’26 Platinum coated ’Cocoon’ Occluder to minimize Nickel leaching Commercialized in 55 markets b/w FY24-Jun’26(1) Published in No device related erosion or allergy “implantation of CSO provided satisfactory procedural and follow-up results with high success and no device-related cardiac erosions and nickel allergy” – Dr. Basil (Vasilios) D. Thanopoulos, IASO Children’s Hospital, Greece Published in CCI JACC HJC FCM CCI: Catheterization and Cardiovascular Interventions, JACC: Journal of the American College of Cardiology HJC: Hellenic Journal of Cardiology, FCM: Frontiers in Cardiovascular Medicine Approval Update AVDC Hydra (no skirt) Hydra Elevate (ext. skirt) CE mark, CDSCO CE mark, CDSCOCDSCO 25
Page 26
Structured teams, working in collaborative environment to launch innovative products Proven R&D Capabilities Across Products and Platform Technologies Robust in-house R&D capabilities ▪ R&D team of 156 members, with several members having Masters and PhDs ▪ Replaced externally sourced balloon catheters with self manufactured balloon catheters leading to cost saving and improved quality control ▪ Track record of safety, efficacy and generating clinical data ▪ R&D spend at ~9–10% of revenue, FY24 to H1 FY27 ▪ Innovation recognized and awarded ‒ “Excellence in Clinical Evidence” for 35,000+ patient clinical program by CSI NIC, 2025 ‒ “CPHI India Pharma 2022 Award in Excellence in R&D - Development of new product/technology” by Informamarkets, 2022 ‒ “National Award 2022 for successful development and commercialization of indigenous technology” by the Technology Development Board (TDB) 814.63 929.86 1,041.64 762.57 FY24 FY25 FY26 H1 FY27 R&D expenditure (INR mn) R&D as % of revenue 9.0% 9.1% 8.6% Global R&D facilities India (DSIR approved) Nonthaburi, Thailand (GMP, CE certified) Robust in-house technologies and IPs Catheter manufacturing Laser cutting Drug coating Drug and polymer formulation Medical grade tubing extrusion Custom equipment design Advanced alloy processing Valve manufacturing Braiding & Lamination Robust IP 118 Patents granted 79 Additional patents in pipeline 5 Design registrations 75 Clinical studies (incl. ongoing) Partnerships Sardar Vallabhbhai National Institute of Technology (SVNIT) Technology Development Board Institute of Chemical Technology 10.5% 26
Page 27
Integrated Manufacturing across India and Thailand with Room to Scale Annual capacity and utilisation by plant, with critical components brought in-house 27 Three plants, globally accredited Sachin SEZ, Surat (India) Telangana (India) Nonthaburi (Thailand) Area utilisation 100% 33% 100% DES 780,000 | 79% 180,000 | 20% – Catheter 660,000 | 72% 600,000 | 57% – TAVI – – 3,600 | 53% Occluder – – 30,000 | 46% Key approvals CE, MDSAP, CDSCO ANVISA and TGA (via MDSAP) ISO 13485:2016 CDSCO ISO 13485:2016 CE, ANVISA, Korean GMP Thai FDA, ISO 13485:2016 Annual capacity (units) | capacity utilisation % Room to scale: Telangana uses only a third of its plant area, leaving space to add DES and catheter capacity as demand grows. Vertical integration Nitinol processing Extrusion and braiding Drug and polymer formulation Laser cutting Valve manufacturing Catheter manufacturing Technologies in-house WIP WIP WIP: capability being built in-house
Page 28
Leadership Team with Global Medtech Experience (1/2) Senior executives with global medtech experience across R&D, manufacturing and business development Bhargav Dhirajlal Kotadia Managing Director & CEO ▪ Joined SMT in 2013 as Executive Director ▪ B.Sc. Economics, Purdue University, USA ▪ “ET 40 under Forty”, The Economic Times ▪ “India’s Impactful Healthcare Leaders 2026”, ET Edge, The Times Group Amit Kumar Khandelia Chief Financial Officer ▪ Over 20 years in finance; ex- Alkem, Cipla and Tata Teleservices ▪ Chartered Accountant; Company Secretary, B.Com, St. Xavier’s College, Kolkata ▪ Alumnus of IIM Ahmedabad ▪ “CA Achiever in the Healthcare Sector”, ICAI, 2018 Anil Suri Chief Commercial Officer ▪ 23 years of experience in sales, and marketing, with tenure in Abbott Vascular; Joined SMT in 2023 ▪ MBA from IIM Indore Piyush Savalia Chief Strategy Officer ▪ 17 years of experience in the field of interventional cardiology ▪ Bachelor of Pharmaceutical Science from Mumbai University Dr. Krishnankutty Sudhir Chief Medical Officer ▪ Over 18 years of experience in organizations like Abbott etc. ▪ Fellow of the Royal Australasian College of Physicians and the Society of Cardiovascular Angiography and Interventions, FSCAI. Priyanka Dhirajlal Cohen Legal Head ▪ 7 years of experience in the field of litigation ; served as a Trial Attorney with the tax division, US Dept. of Justice ▪ Juris Doctor cum Laude from Washington College of Law, American University, 28
Page 29
Leadership Team with Global Medtech Experience (2/2) Senior executives with global medtech experience across R&D, manufacturing and business development Manoj Jain Senior Vice President – Quality & Regulatory Affairs ▪ 28 years of with expertise in QA, risk management, reg. affairs, and ops. excellence with tenure in Boston Scientific, Biomet Microfixation ▪ Master’s degree in Engg. Mgmt. from Syracuse University, USA Russell Rozario Senior Vice President - Human Resources ▪ 30 years of experience in HR with tenure in Metropolis, Unisource etc.; 8+ years with SMT ▪ B.Sc. Chemistry from K.J. Somaiya College of Science, Diploma in HR from Welingkar Institute of Management Girish Kewalramani Chief Information Technology ▪ 24 years of experience in IT across CEAT, Lupin, Indokem and Seforge, 7+ years with SMT ▪ Graduated from Maharshi Dayanand Saraswati University Abhijeet Singhvi Chief Technology Officer ▪ 17 years of experience in quality assurance and product compliance with tenure in Boston Scientific, Marlborough; 16 yrs. with SMT ▪ Master in Biomedical Engineering from Worcester Polytechnic Institute (MA, USA) 29
Page 30
Experienced Board Guiding SMT’s Next Phase of Growth Board of Directors Dhirajlal Kotadia Chairman Emeritus and Non-Executive Director Sonalika Girdharilal Dhar Independent Director Global Head - Strategic Investments and Business Development- UPL Limited Past Organisations– Edelwiess, KPMG Bhargav Dhirajlal Kotadia Managing Director and CEO Abhishek Rajendrakumar Kabra Non-Executive Director MD, Samara Capital Debasis Panigrahi Independent Director Designated Partner – Mridayaa Ventures, Past Organisations– Nomura Jose Calle Gordo Chairperson and Non-Executive Director Past Organisations - Biosensors & Abbott Harvinder Pal Singh Independent Director Executive VP & President International– Integra LifeSciences Corporation, Past Organisations- Abbott Chaired by a 37-year medtech veteran Priyanka Dhirajlal Cohen Non-Executive Director Past Organisations– Trial Attorney, US Dept. of Justice 30
Page 31
Thank You Investor Relations investor.relations@smt.in Sahajanand Medical Technologies Limited Corporate Office: 402 & 412, A-Wing, Kanakia Wall Street, Andheri-Kurla Road, Chakala, Andheri (East), Mumbai, Maharashtra – 400 093